Across TCGA pan-cancer cohorts, SNORA70E RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of SNORA70E’s most consistent transcriptional readouts.
The strongest signal is observed in breast invasive carcinoma (BRCA), where SNORA70E RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SNORA70E is over-expressed in tumor.
BRCA and LUAD are the cancer types where SNORA70E tumor–normal differential expression is most reproducible.